2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
2015
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women
Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, Schapira L, Come SE, Borges VF, Schedin P, Warner E, Wensley T, Tamimi RM, Winer EP, Partridge AH. Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. The Oncologist 2015, 20: 713-718. PMID: 26025931, PMCID: PMC4492229, DOI: 10.1634/theoncologist.2014-0412.Peer-Reviewed Original ResearchConceptsBreast cancer molecular phenotypesBreast cancerYoung womenFamily historyPregnancy-associated breast cancerMolecular phenotypesTumor histologic gradeBreast cancer riskBreast cancer phenotypeLast pregnancyParous womenProspective cohortCentral reviewHistologic gradeLike subtypeMolecular subtypesLarge cohortCancer riskPregnancyClinical practiceStudy questionnaireBiomarker expressionCancerTumor phenotypeWomenRacial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal Of Clinical Oncology 2015, 33: 2254-2261. PMID: 25964252, PMCID: PMC4486344, DOI: 10.1200/jco.2014.57.1349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAsianBiomarkers, TumorBlack or African AmericanBody Mass IndexBreast NeoplasmsCause of DeathDisease-Free SurvivalEthnicityFemaleHealth Status DisparitiesHealthcare DisparitiesHispanic or LatinoHumansLogistic ModelsMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm StagingProportional Hazards ModelsRacial GroupsRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsBreast cancer-specific survivalEstrogen receptor-positive tumorsCancer-specific survivalReceptor-positive tumorsBreast cancer survivalTumor characteristicsCancer survivalBreast cancerNational Comprehensive Cancer Network centersBreast cancer-specific deathHuman epidermal growth factor receptorCancer-specific deathMultivariable adjusted modelsYear of diagnosisBody mass indexProportional hazards regressionEpidermal growth factor receptorRace/ethnicityGrowth factor receptorHazards regressionMass indexRisk factorsSurvival differencesLike tumorsHigh riskVariation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study
Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study. Cancer 2015, 121: 1937-1948. PMID: 25757412, PMCID: PMC4457605, DOI: 10.1002/cncr.29310.Peer-Reviewed Original ResearchConceptsStage I breast cancerI breast cancerHuman epidermal growth factor receptor 2Breast cancerAdjuvant chemotherapyIntensive regimensNational Comprehensive Cancer Network centersEpidermal growth factor receptor 2Choice of regimenHER2-negative diseaseHER2-positive diseaseCombination of docetaxelPercentage of patientsProspective cohort studyType of chemotherapyGrowth factor receptor 2Time of diagnosisAmerican Joint CommitteeMultivariable logistic regressionFactor receptor 2Multi-institutional studyCommon regimensChemotherapy regimensIntensive chemotherapyCohort study
2014
Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study. Journal Of Clinical Oncology 2014, 32: 927-934. PMID: 24516021, PMCID: PMC3948095, DOI: 10.1200/jco.2013.51.1261.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerCardiac eventsOlder patientsBreast cancerTrastuzumab completionAdjuvant trastuzumabTreatment completionOlder womenHuman epidermal growth factor receptorAdjuvant trastuzumab useAge 76 yearsDays of therapyMost older patientsSignificant cardiac eventsMultivariable logistic regressionEpidermal growth factor receptorGrowth factor receptorMore comorbiditiesTrastuzumab useComorbidity scorePatient ageHospital admissionOptimal treatmentLower oddsMedicare data
2010
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett E, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N, B F. Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. Journal Of The National Cancer Institute 2010, 102: 942-949. PMID: 20554945, PMCID: PMC2897879, DOI: 10.1093/jnci/djq211.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantEstrogen Receptor ModulatorsFactor VFemaleHumansLogistic ModelsMiddle AgedMultivariate AnalysisMutationOdds RatioPrevalenceRisk FactorsSelective Estrogen Receptor ModulatorsSmokingTamoxifenThromboembolismConceptsFactor V LeidenEarly-stage breast cancerThromboembolic eventsAdjuvant tamoxifenFVL mutationBreast cancerTamoxifen useTE riskControl subjectsOdds ratioFactor V Leiden mutationCase-control studyConditional logistic regressionV Leiden mutationPostmenopausal womenThromboembolism riskThrombosis riskMultivariable modelTherapeutic decisionsV LeidenLeiden mutationHigh riskPositive testTamoxifenCancerAdherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal Of Clinical Oncology 2010, 28: 2418-2422. PMID: 20368559, PMCID: PMC2881723, DOI: 10.1200/jco.2009.26.4671.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAge FactorsAgedAged, 80 and overAntimetabolites, AntineoplasticBreast NeoplasmsCanadaCapecitabineChemotherapy, AdjuvantDeoxycytidineDrug Administration ScheduleDrug MonitoringFemaleFluorouracilHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMastectomyMedication AdherenceMicro-Electrical-Mechanical SystemsNeoplasm StagingRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsEarly-stage breast cancerBreast cancerCALGB 49907Oral chemotherapyClinical trialsOlder womenPatients age 65 yearsOral adjuvant chemotherapyPill bottle openingsNode-negative diseaseHormone receptor statusRelapse-free survivalRandomized clinical trialsAge 65 yearsMulticenter clinical trialNumber of dosesPercent of participantsLogistic regression modelsAdjuvant chemotherapyProtocol therapyOral therapyStandard chemotherapyMedian ageReceptor statusPatient adherence
2009
Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women
Kouri EM, He Y, Winer EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Research And Treatment 2009, 121: 743-751. PMID: 19949856, DOI: 10.1007/s10549-009-0643-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesEarly DiagnosisEmigrants and ImmigrantsFemaleHealth Services AccessibilityHealth Status DisparitiesHispanic or LatinoHumansLogistic ModelsMastectomy, SegmentalMiddle AgedMultivariate AnalysisRadiotherapy, AdjuvantResidence CharacteristicsRisk FactorsUnited StatesConceptsBreast cancerHispanic womenBreast cancer diagnosisRace/ethnicityPrimary therapyWhite womenStage I breast cancerNon-Hispanic white womenCancer diagnosisEarly-stage diseaseI breast cancerInvasive breast cancerAssociation of ethnicityForeign-born HispanicsInfluence of birthplaceTherapy differsTumor characteristicsSEER areasFirst diagnosisRates of stageAdjusted ratesMultinomial logistic regressionStage IAdvanced stageAppropriate interventionsRacial Differences in Definitive Breast Cancer Therapy in Older Women
Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial Differences in Definitive Breast Cancer Therapy in Older Women. Medical Care 2009, 47: 765-773. PMID: 19536008, DOI: 10.1097/mlr.0b013e31819e1fe7.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBlack or African AmericanBreast NeoplasmsChi-Square DistributionFemaleHealth Services ResearchHealthcare DisparitiesHospitalsHumansLogistic ModelsMastectomyMedicareMultivariate AnalysisPractice Patterns, Physicians'Quality of Health CareSEER ProgramSensitivity and SpecificitySocioeconomic FactorsUnited StatesWhite PeopleConceptsHigh-volume hospitalsDefinitive primary therapyHigh-quality hospitalsBreast-conserving surgeryBreast cancer therapyBreast cancerPrimary therapyWhite womenRacial disparitiesStage I/II breast cancerBlack womenPrimary breast cancer therapyEarly-stage breast cancerLow-volume hospitalsBreast cancer patientsBreast cancer surgeryPatterns of careSEER-Medicare databaseCancer therapyPopulation-based sampleOlder Black womenDefinitive therapyVolume hospitalsCancer surgeryCancer patients
2008
Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B
Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B. Journal Of Clinical Oncology 2008, 26: 2659-2665. PMID: 18509177, PMCID: PMC4830463, DOI: 10.1200/jco.2007.13.9782.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerHazard of deathTreatment failureBreast cancerOverall survivalClinical outcomesLeukemia Group B trialAfrican AmericansLeukemia Group BMedian overall survivalTreatment-related toxicityObserved survival differencesTime of presentationAfrican American patientsRacial differencesOverall responseAfrican American womenLarge cooperative groupsMetastatic settingProtocol treatmentPrognostic factorsStudy cohortSubsequent therapyShorter survivalPooled analysisRisk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study
Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study. Journal Of The National Cancer Institute 2008, 100: 243-251. PMID: 18270338, DOI: 10.1093/jnci/djn010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnxietyBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCohort StudiesDepressionFemaleHumansLogistic ModelsLongitudinal StudiesMammographyMass ScreeningMassachusettsMiddle AgedNeoplasm Recurrence, LocalOdds RatioPredictive Value of TestsPrognosisQuality of LifeRisk AssessmentRisk FactorsConceptsLocal recurrence rateRecurrence ratePsychosocial outcomesDuctal carcinomaModerate riskCancer-related risksFavorable overall prognosisSystemic recurrence ratesBreast-conserving treatmentBreast cancer riskDCIS diagnosisCohort studyDCIS recurrenceOverall prognosisDisease recurrenceInvasive cancerDCISCancer riskPsychosocial concernsHealth behaviorsEnrollment surveySubstantial anxietyWomenInaccurate perceptionsModerate likelihood
2007
Surveillance Testing Among Survivors of Early-Stage Breast Cancer
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance Testing Among Survivors of Early-Stage Breast Cancer. Journal Of Clinical Oncology 2007, 25: 1074-1081. PMID: 17369571, DOI: 10.1200/jco.2006.08.6876.Peer-Reviewed Original ResearchMeSH KeywordsAgedBreast NeoplasmsCohort StudiesDiagnostic Tests, RoutineFemaleFollow-Up StudiesGuideline AdherenceHumansLogistic ModelsLong-Term CareMedical OncologyNeoplasm StagingOdds RatioOffice VisitsPopulation SurveillancePractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareSEER ProgramSurvivorsTime FactorsUnited StatesUnnecessary ProceduresConceptsBreast cancer survivorsChest X-rayMedical oncologistsCancer survivorsBreast cancerAbdominal imagingAntigen testingBone scanStage I/II breast cancerEarly-stage breast cancer patientsMost breast cancer survivorsEnd Results-Medicare dataSurveillance testingEarly-stage breast cancerRepeated-measures logistic regressionBreast cancer patientsLow-risk populationPopulation-based cohortTypes of physiciansRoutine surveillance testingRate of testingAntigen testCancer patientsWomen's ageSurveillance years
2005
The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries
Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries. Journal Of General Internal Medicine 2005, 20: 38-44. PMID: 15693926, PMCID: PMC1490029, DOI: 10.1111/j.1525-1497.2004.40079.x.Peer-Reviewed Original ResearchConceptsPrimary care physiciansCare physiciansBreast cancer diagnosisAdvanced cancerOutpatient careNumber of visitsMedical specialistsAdvanced stage diagnosisPreventive care visitsRetrospective cohort studyCancer diagnosisBreast cancer stagePercent of womenPopulation-based sampleCare visitsCohort studyCancer RegistryCancer stageUse of servicesElderly womenAdjusted ratesBreast cancerLower median incomeAmbulatory careHigh risk
2004
Web-Based Survey of Fertility Issues in Young Women With Breast Cancer
Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-Based Survey of Fertility Issues in Young Women With Breast Cancer. Journal Of Clinical Oncology 2004, 22: 4174-4183. PMID: 15483028, DOI: 10.1200/jco.2004.01.159.Peer-Reviewed Original ResearchMeSH KeywordsAdultAttitude to HealthBreast NeoplasmsChemotherapy, AdjuvantFemaleFertilityHumansLogistic ModelsMenopauseRiskConceptsPercent of womenBreast cancerYoung womenFertility issuesEarly-stage breast cancerYoung breast cancer survivorsYear of diagnosisBreast cancer survivorsMultivariate logistic regressionE-mail remindersBreast cancer diagnosisPrior pregnancyYounger patientsCancer survivorsFertility concernsTreatment decisionsWeb-based surveyEligible respondentsInfertility concernsLogistic regressionCancerDiagnosisCancer diagnosisWomenMore childrenFailure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. Journal Of Clinical Oncology 2004, 22: 2061-2068. PMID: 15169793, DOI: 10.1200/jco.2004.08.048.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerQuality of lifeOptimal doseResponse rateSignificant dose-response relationshipHigh-dose armPrior chemotherapy regimensHigh-dose therapySymptom assessment questionnaireCycles of treatmentSelf-administered qualitySignificant differencesDose-response relationshipChemotherapy regimensDose therapyHematologic toxicityDose armAssessment QuestionnaireHigh dosesMultivariate analysisSignificant associationInfusionCancerRegimens
2003
Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer.
Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. Journal Of Clinical Oncology 2003, 21: 4532-9. PMID: 14673040, DOI: 10.1200/jco.2003.05.131.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryDefinitive surgeryMedical oncologistsType of surgeryElderly womenAxillary dissectionBreast cancerEarly-stage breast cancerGuideline-recommended careRetrospective cohort studyAxillary node dissectionBreast cancer treatmentPercent of womenPopulation-based sampleComorbid illnessesNode dissectionCohort studyGuideline recommendationsDifferentiated cancerTeaching hospitalAdjusted proportionSurgeryOncologistsCancer treatmentWomen
1998
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal Of Clinical Oncology 1998, 16: 2417-25. PMID: 9667259, DOI: 10.1200/jco.1998.16.7.2417.Peer-Reviewed Original Research